Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Jan;62(1):9-17.
doi: 10.2337/db12-0562.

Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials

Teodora P Staeva  1 , Lucienne Chatenoud, Richard Insel, Mark A Atkinson
Affiliations
Review

Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials

Teodora P Staeva et al. Diabetes. 2013 Jan.
No abstract available

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Immunotherapies clinically tested or under testing in recent-onset T1D. Interventions appearing in bold represent therapies reported in trial results during the past 20 months. APL, altered peptide ligand; CTX, Cyclophosphamide (Cytoxan); HSC, hematopoietic stem cell; Hsp, heat shock protein; IFA, incomplete Freund's adjuvant; IL-1Ra, interleukin-1 receptor antagonist; MMF, mycophenolate mofetil; MSC, mesenchymal stem cell; UCB, umbilical cord blood.
FIG. 2.
FIG. 2.
Effect of cyclosporine treatment on T1D remission rates, as reported by the Cyclosporine Diabetes French Study (15). CsA, cyclosporin A.
FIG. 3.
FIG. 3.
Key emerging questions in the field of T1D prevention and reversal.
FIG. 4.
FIG. 4.
Key recommendations to improve efforts, moving forward, in terms of immunotherapies directed at attenuating T1D.
See this image and copyright information in PMC

References

    1. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221–229 - PubMed
    1. Eizirik DL, Colli ML, Ortis F. The role of inflammation in insulitis and beta-cell loss in type 1 diabetes. Nat Rev Endocrinol 2009;5:219–226 - PubMed
    1. Bluestone JA, Herold K, Eisenbarth G. Genetics, pathogenesis and clinical interventions in type 1 diabetes. Nature 2010;464:1293–1300 - PMC - PubMed
    1. Bach JF, Chatenoud L. A historical view from thirty eventful years of immunotherapy in autoimmune diabetes. Semin Immunol 2011;23:174–181 - PubMed
    1. Skyler JS, Ricordi C. Stopping type 1 diabetes: attempts to prevent or cure type 1 diabetes in man. Diabetes 2011;60:1–8 - PMC - PubMed

MeSH terms